TPG explores $5B sale of healthcare software firm Lyric

Seeking Alpha··US·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

TPG Inc. is evaluating the sale of its Lyric business in a transaction that could value the healthcare software company at about $5 billion. TPG is working with JPMorgan Chase on a potential sale, according to a Reuters report citing people familiar with the matter, though there is no guarantee a deal will happen. Lyric generates about $250 million in EBITDA, which could support a $5 billion valuation at a 20 times multiple. TPG purchased ClaimsXten for about $2.2 billion in 2022 and rebranded it Lyric the following year. TPG and JPMorgan declined comment, and Lyric did not immediately respond to a request for comment.

Impact on assets 2

Financials▲ · 1 stocks
TPG Inc
TPG
▲ PositiveCapitalrelevance

TPG is exploring a ~$5B sale of its Lyric healthcare software unit, a potential exit/valuation event for the firm.

Digital Finance & Tokenization▲ · 1 stocks
JPMorgan Chase & Co
JPM
± MixedCapitalrelevance

JPMorgan is advising TPG on the potential ~$5B Lyric sale, a passing advisory role with no clear financial impact.

Off-coverage companies 1

LyricPrivate± Mixed
Capitalrelevance

Lyric is the subject of a potential ~$5B sale by owner TPG, but no deal is guaranteed.

© 2026 MarketIVNews